newsfilter
← Earnings
Earnings Releases·

Bicycle Therapeutics — Third Quarter 2026 Earnings Summary

  • Collaboration revenue surged to $34.1 million in Q3 2026 from $11.7 million in 2025, while net loss narrowed significantly to $10.5 million ($0.15 per share) from $59.1 million ($0.85 per share) in the prior year period.
  • Operating expenses declined sharply, with R&D dropping to $33.4 million from $58.4 million and G&A falling to $14.1 million from $18.9 million, driven by the termination of the Bayer Consumer Care AG collaboration and workforce reductions in August 2025 and March 2026.
  • The nuzefatide program received FDA Orphan Drug Designation for pancreatic cancer in September 2026, with the company actively enrolling in Phase 2 trials and expecting updates in 2027.
  • Management deprioritized the zelenectide program for internal development, converting its Duravelo-2 trial to a randomized Phase 2 design with survival data expected in late 2027, while planning to initiate the first company-sponsored radioligand trial for BT1702 in the second half of 2027.
  • Cash and cash equivalents stood at $469.9 million as of September 30, 2026, supporting a projected cash runway extending into 2030.
Company
BICYCLE THERAPEUTICS PLC
Sector
Healthcare
Industry
Biotechnology